Ingen Technologies, Inc. engages in the manufacture of respiratory medical devices. The company is headquartered in Riverside, California. The company went IPO on 2001-07-11. The firm holds the manufacturing and marketing platforms to produce its core medical product line, referred to as Oxyview and Smart Nasal Cannula. The firm develops products for the treatment of chronic obstructive pulmonary disease (COPD), such as chronic bronchitis, emphysema and asthmatic bronchitis, all of which obstruct airflow from the lungs. The Company’s products include The Smart Nasal Cannula 206NCA (Adult Size), The Smart Nasal Cannula 203NCA (Adult Size), The Smart Nasal Cannula 206NCP (Child Size), The Smart Nasal Cannula 203NCP (Child Size), The Smart Nasal Cannula 206NC (Infant Size), The Smart Nasal Cannula 203NC (Infant Size), Oxyview 203A And Oxyview 206A.
Ingen Technologies Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Ingen Technologies Incの収益はセグメントまたは地域別にどのように分けられていますか?
Ingen Technologies Inc の最大収益セグメントは Coal Mining in New South Wales で、最新の利益発表における収益は 1,559,726,000 です。地域別に見ると、Japan が Ingen Technologies Inc の主要市場であり、収益は 844,093,000 です。